Insight Partners' Parekh defends diversified AI strategy as rivals concentrate bets
Insight Partners co-leader Devin Parekh discussed the firm's deliberate diversification strategy amid a venture capital rush into frontier AI labs. He expressed optimism about AI's potential in healthcare, citing examples like analyzing patient records, while acknowledging some risks. Parekh also explained the firm's preference for letting portfolio performance speak over being publicly vocal.
Insight Partners manages roughly $90 billion and has backed major AI players including OpenAI, Anthropic, and Databricks. The firm's strategy spans early-stage, growth, and buyout deals, though it has paused major buyouts since 2024 due to high rates and weak software debt markets. Parekh noted that recent venture rounds move so quickly that investors pay premium prices without gaining meaningful new data, pushing the firm toward earlier, smaller checks.
Parekh, who serves on NYU Langone's board, pointed to AI's ability to scan millions of patient records and flag health risks as evidence of the technology's upside. The firm lost a competitive bid for legal-tech startup Legora to General Catalyst, despite partner Jeff Horing traveling to Stockholm to pitch the founder. Parekh also acknowledged that AI infrastructure talent remains heavily concentrated in San Francisco.
The debate over AI risk versus reward could shape how venture capital allocates billions in coming years. If diversified investors like Insight Partners prove that broad AI applications in healthcare and enterprise deliver returns, it may temper the current concentration of capital in frontier labs. However, the rapid pace of AI dealmaking could also inflate valuations, potentially exposing limited partners to losses if the market corrects, as it did after 2021.